Minprostin E2 (Dinoprostone)

Dinoprostone binds to EP receptors in the uterus and cervix, raising intracellular calcium and activating enzymes that remodel cervical tissue. This leads to cervical softening, dilation, and stimulates uterine muscle contractions, facilitating labor or termination processes.

The specific dose and regimen of Minprostin E2 are determined by the prescribing clinician based on the indication, gestational age, and patient condition. Healthcare providers follow local guidelines and product labeling to set the appropriate dosing schedule.

Minprostin E2 is intended for use during pregnancy when cervical ripening or labor induction is required. It is not recommended for use in women who are not pregnant. Safety during breastfeeding has not been established, and the product should be used only under medical advice.

To request Minprostin E2, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both dinoprostone (Minprostin E2) and misoprostol are prostaglandin analogs used for cervical ripening and labor induction. Dinoprostone is a direct prostaglandin E2 analog with a shorter half‑life, while misoprostol is a prostaglandin E1 analog often used orally or vaginally. Choice depends on clinical protocol, availability, and patient-specific factors.

Minprostin E2 should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Minprostin E2 is administered vaginally, typically as a tablet or insert placed in the posterior fornix of the vagina. The exact method and timing are determined by the treating clinician, who monitors the patient for cervical changes and uterine activity.

Serious risks include uterine hyperstimulation, uterine rupture, severe hemorrhage, fetal distress, and rare allergic reactions such as anaphylaxis. Continuous fetal and maternal monitoring is essential during treatment to detect and manage these complications promptly.

Minprostin E2 should be avoided in women with active vaginal bleeding, prior uterine surgery (e.g., cesarean section), known hypersensitivity to prostaglandins, or any condition where uterine stimulation is contraindicated. A thorough medical assessment is required before initiation.